|
The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) Clinical research trials and The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF). The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) clinical trial. Human subjects often get the best healthcare possible for their The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)  The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
For Condition: Idiopathic Pulmonary Fibrosis,Lung Disease,Pulmonary Fibrosis
Status: Recruiting
Sponsor(s): InterMune ,
Synopsis: - Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF - Enrollment: 600 patients will be enrolled from approximately 70 centers in North America and Europe - Randomization: 2:1 active-to-placebo ratio - Duration: 2 years active drug or placebo (rescue therapy will be permitted for patients who meet predefined criteria)
Details: INSPIRE, the largest and most comprehensive clinical trial ever conducted in IPF, is now enrolling patients with mild to moderate IPF. Eligible patients will receive either Interferon gamma-1b or placebo for a minimum of 2 years.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 40 Years/79 Years
Genders: Both
Protocol Entry Criteria: - Ages 40-79 - Diagnosis of IPF based on ATS/ERS criteria within past 36 months - Definite or probable IPF on high-resolution computed tomography (HRCT) - Surgical lung biopsy or nondiagnostic bronchoscopy - Evidence of disease progression within past year - FVC within 55-90% of predicted value - DLCO within 35-90% of predicted value
Total Enrollment: 600
Location and Contact Information:
InterMune, Inc. *Recruiting*
Brisbane, California, 94005
United States
Recruiting INSPIRE Trial
Additional Information:
Study ID Numbers: GIPF-007;
Study Start Date: December 2003
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00075998
Other Lung Disease Studies:
1. Evaluation of the Causes and Disease Processes of Chronic Lung Disease
2. Benefits and Risks of Newborn Screening for Cystic Fibrosis
3. Effects of Endotoxin in Normal Human Volunteers
4. A Randomized, Double-Blind, Three-arm, Phase 3b Study Comparing the Safety and efficacy of Interferon gamma-1b with Azatioprine, and Azathioprine Alone in Patients with IPF Receiving Prednisone
5. Inhaled Nitric Oxide in Neonates with Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation
Related Studies:
Other Lung Disease Clinical Trials
Other California Clinical Trials
Other Brisbane Clinical Trials
The INSPIRE Trial: A Study of Interferon gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
|
|
|
|
|
|
|
|
